Gemtuzumab in Treating Patients With Myelodysplastic Syndrome
Status:
Unknown status
Trial end date:
1969-12-31
Target enrollment:
Participant gender:
Summary
RATIONALE: Monoclonal antibodies such as gemtuzumab can locate tumor cells and either kill
them or deliver tumor-killing substances to them without harming normal cells.
PURPOSE: Randomized phase II trial to study the effectiveness of gemtuzumab in treating
patients who have myelodysplastic syndrome.